The pharmaceuticalindustry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Bridged diaryl derivatives-based cancer drug compositions.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 areas of innovation that will shape the future of the industry.
Bridged diaryl derivatives-based cancer drug compositions is a key innovation area in immuno-oncology
Diaryl-ether is a scaffold found in natural products, synthetic organic compounds, and innovative molecules. Owing to its unique physicochemical properties and potential biological activities, it is widely used in anti-cancer, anti-diabetic, and anti-tubercular agents. Diaryl-ethers can be synthesised in three ways, including Ullmann ether synthesis, Buchwald Pd-catalysed ether synthesis and via aromatic nucleophilic substitution (SNAr)-based addition reactions. Based on the ease of synthesis and its biological activity, the bridged diaryl skeleton structure is widely used for anti-cancer drugs.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of bridged diaryl derivatives-based cancer drug compositions.
Key players in bridged diaryl derivatives-based cancer drug compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to bridged diaryl derivatives-based cancer drug compositions
Source: GlobalData Patent Analytics
Turning Point Therapeutics (now part of Bristol-Myers Squibb) is a leader in developing diaryl derivatives-based anti-cancer drugs. The company has filed several patents and is developing drugs such as repotrectinib for the treatment of solid tumours. Repotrectinib is in Phase II clinical trials for multiple oncology indications. The company has also partnered with ZaiLab for its development in China.
In terms of application diversity, AbTis is the top company followed by Bayer and Astro Bidco. By geographic reach, Enanta Pharmaceuticals holds the top position. Gilead Sciences and Eurofins Scientific are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.